The role of intranasal steroid therapy in the treatment of chronic sinusitis with nasal polyps
https://doi.org/10.21518/2079-701X-2021-6-74-80
Abstract
Polypoid rhinosinusitis (PRS) is a form of chronic rhinosinusitis (CRS), which is a heterogeneous group of pathological conditions based on a chronic inflammatory process of the nasal cavity and paranasal sinuses (PNS), leading to polypoid tissue formation. In most cases, T2-inflammation underlies the pathogenetic mechanism of PRS. In the presence of T2-associated conditions, the course of PRS is usually severe. The main aim of PRS treatment is to control symptoms, prolong the recurrence-free period, and restore the aeration of the PNS. The basic therapy of PRS involves the use of intranasal glucocorticosteroids (InGCS), which have a nonspecific anti-inflammatory effect by acting on different points of the pathological inflammatory process. The level of evidence for the use of InGCS is Ia: the drugs are included in Russian and foreign clinical guidelines for the treatment of polypoid rhinosinusitis. InGCS have high topical activity at low steroid doses. Mometasone furoate has an important place among this group of drugs because of its high efficacy, long-lasting therapeutic effect and optimal safety profile. The drug is officially registered for the treatment of PRS. Long-term use of mometazone furoate has been clinically observed to cause almost no atrophic nasal mucosal changes. It can be administered as monotherapy and in combination therapy over long periods of time in all phases of the treatment of PRS.
About the Authors
V. P. Sobolev
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Vasiliy P. Sobolev, Cand. Sci. (Med.), Associate Professor, Associate Professor of the Department of Ear, Throat and Nose Diseases of Sklifosovsky Institute of Clinical Medicine
8, Bldg. 2, Trubetskaya St., Moscow, 119991
D. B. Bidanova
Research Center of Neurology
Russian Federation
Russian Federation
Darima B. Bidanova, otorhinolaryngologist
14, Vorontsovo Pole St., Moscow, 105064
References
1. Lopatin A.S. (ed.). Chronic Rhinosinusitis: Pathogenesis, Diagnosis and Treatment Principles: (Clinical Recommendations). Moscow: Prakticheskaya meditsina; 2014. 64 p. (In Russ.) Available at: https://osp.ru/netcat_files/userfiles/lvrach/Sinusit-recommendations.pdf.
2. Fokkens W.J., Lund V.J., Hopkins C., Hellings P.W., Kern R., Reitsma S. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(S29 Suppl.):1–464. doi: 10.4193/Rhin20.600.
3. Lange B., Holst R., Thilsing T., Baelum J., Kjeldsen A. Quality of Life and Associated Factors in Persons with Chronic Rhinosinusitis in the General Population. Clin Otolaryngol. 2013;38(6):474–480. doi: 10.1111/coa.12189.
4. Brescia G., Zanotti C., Parrino D., Barion U., Marioni G. Nasal Polyposis Pathophysiology: Endotype and Phenotype Open Issues. Am J Otolaryngol. 2018;39(4):441–444. doi: 10.1016/j.amjoto.2018.03.020.
5. Hopkins C. Chronic Rhinosinusitis with Nasal Polyps. N Engl J Med. 2019;381(1):55–63. doi: 10.1056/NEJMcp1800215.
6. Bradley D.T., Kountakis SE. Role of Interleukins and Transforming Growth Factor-Beta in Chronic Rhinosinusitis and Nasal Polyposis. Laryngoscope. 2005;115(4):684–686. doi: 10.1097/01.mlg.0000161334.67977.5D.
7. Piskunov G.Z. Clinical Phenotypes of Polyposis Rhinosinusitis. Rossiyskaya rinologiya = Russian Rhinology. 2019;27(4):224–231. (In Russ.) doi: 10.17116/rosrino201927041224.
8. Schleimer R.P. Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. Annu Rev Pathol. 2017;12:331–357. doi: 10.1146/annurevpathol-052016-100401.
9. Kryukov A.I., Turovsky A.B., Sedinkin A.A. Diagnostics and Treatment of Polypous Rhinosinusitis. RMZH = RMJ. 2011;(6):377–380. (In Russ.) Available at: https://rmj.ru/articles/otorinolaringologiya/Diagnostika_i_lechenie_polipoznogo_sinusita/.
10. Newton J.R., Ah-See K.W. A Review of Nasal Polyposis. Ther Clin Risk Manag. 2008;4(2):507–512. doi: 10.2147/tcrm.s2379.
11. Savlevich E.L., Kurbacheva O.M. Features of the Course of Polypous Rhinosinusitis Combined with Allergic Rhinitis. Meditsinskiy sovet = Medical Council. 2019;(20):38–43. (In Russ.) doi: 10.21518/2079-701X-2019-20-38-43.
12. Ozturan A., Eyigor H., Eyigor M., Osma U., Yilmaz M.D., Selcuk O.T., Renda L., Gultekin M. The role of IL-25 and IL-33 in chronic rhinosinusitis with or without nasal polyps. Eur Arch Otorhinolaryngol. 2017;274(1):283–288. doi: 10.1007/s00405-016-4260-6.
13. Chichkova N.V. Bronchial Asthma and Polyposis Rhinosinusitis: Clinical Features and Management Tactics. Astma i allergiya = Asthma and Allergy. 2015;(1):19–22. (In Russ.) Available at: https://cyberleninka.ru/article/n/bronhialnaya-astma-i-polipoznyy-rinosinusit-osobennosti-klinicheskogotecheniya-i-taktika-vedeniya-bolnyh.
14. Wu D., Bleier B.S., Li L., Zhan X., Zhang L., Lv Q. et al. Clinical Phenotypes of Nasal Polyps and Comorbid Asthma Based on Cluster Analysis of Disease History. J Allergy Clin Immunol Pract. 2018;6(4):1297–1305.e1. doi: 10.1016/j.jaip.2017.09.020.
15. Castillo Vizuete J.A., Sastre J., Del Cuvillo Bernal A., Picado C., Martínez Moragón E., Ignacio García J.M. et al. Asthma, Rhinitis, and Nasal Polyp Multimorbidities. Arch Bronconeumol. 2019;55(3):146–155. doi: 10.1016/j.arbres.2018.09.001.
16. DeConde A. S., Bodner T.E., Mace J.C., Alt J.A., Rudmik L., Smith T.L. Development of a Clinically Relevant Endoscopic Grading System for Chronic Rhinosinusitis Using Canonical Correlation Analysis. Int Forum Allergy Rhinol. 2016;6(5):478–485. doi: 10.1002/alr.21683.
17. Stevens W.W., Schleimer R.P., Kern R.C. Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2016;4(4):565–572. doi: 10.1016/j.jaip.2016.04.012.
18. Kwah J.H., Peters A.T. Nasal polyps and rhinosinusitis. Allergy Asthma Proc. 2019;40(6):380–384. doi: 10.2500/aap.2019.40.4252.
19. Maxfield A.Z., Landegger L.D., Brook C.D., Lehmann A.E., Campbell A.P., Bergmark R.W. et al. Periostin as a Biomarker for Nasal Polyps in Chronic Rhinosinusitis. Otolaryngol Head Neck Surg. 2018;158(1):181–186. doi: 10.1177/0194599817737967.
20. Le P.T., Soler Z.M., Jones R., Mattos J.L., Nguyen S.A., Schlosser R.J. Systematic Review and Meta-analysis of SNOT-22 Outcomes after Surgery for Chronic Rhinosinusitis with Nasal Polyposis. Otolaryngol Head Neck Surg. 2018;159(3):414–423. doi: 10.1177/0194599818773065.
21. Jankowski R. Eosinophils in the Pathophysiology of Nasal Polyposis. Acta Otolaryngol. 1996;116(2):160–163. doi: 10.3109/00016489609137813.
22. Svistushkin V.M., Chichkova N.V., Pshonkina D.M. Eosinophilia as a Predictor of Recurrent Course Polypoid Rhinosinusitis after Surgical Treatment. Consilium Medicum. 2019;21(11):34–37. (In Russ.) Available at: https://consilium.orscience.ru/archive/2019/tom-21-11-2019/eozinofiliyakak-prediktor-rannego-retsidiva-polipoznogo-rinosinusita-posle-khirurgicheskogo-lecheni_6390/?element.
23. Fokkens W.J., Lund V., Bachert C., Mullol J., Bjermer L., Bousquet J. et al. EUFOREA Consensus on Biologics for CRSwNP with or without Asthma. Allergy. 2019;74(12):2312–2319. doi: 10.1111/all.13875.
24. Bachert C., Zhang N., Cavaliere C., Weiping W., Gevaert E., Krysko O. Biologics for Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol. 2020;145(3):725–739. doi: 10.1016/j.jaci.2020.01.020.
25. Hoy S.M. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps. Drugs. 2020;80(7):711–717. doi: 10.1007/s40265-020-01298-9.
26. Savlevich E.L., Cherenkova V.A., Molodnitskaya A.Yu. Basic Principles for the Treatment of Chronic Rhinosinusitis with Nasal Polyps. Meditsinskiy sovet = Medical Council. 2020;(16):73–78. (In Russ.) doi: 10.21518/2079-701X-2020-16-73-78.
27. Georgalas C., Cornet M., Adriaensen G., Reinartz S., Holland C., Prokopakis E., Fokkens W. Evidence-Based Surgery for Chronic Rhinosinusitis with and without Nasal Polyps. Curr Allergy Asthma Rep. 2014;14(4):427. doi: 10.1007/s11882-014-0427-7.
28. Eloy P., Andrews P., Poirrier A.L. Postoperative Care in Endoscopic Sinus Surgery: A Critical Review. Curr Opin Otolaryngol Head Neck Surg. 2017;25(1):35–42. doi: 10.1097/MOO.0000000000000332.
29. Savlevich E.L., Egorov V.I., Shachnev K.N., Tatarenko N.G. Analysis of Treatment Regimens for Polyposis Rhinosinusitis in the Russian Federation. Rossijskaya otorinolaringologiya = Russian Otorhinolaryngology. 2019;18(1):124–134. (In Russ.) doi: 10.18692/1810-4800-2019-1-124-134.
30. Loftus C.A., Soler Z.M., Koochakzadeh S., Desiato V.M., Yoo F., Nguyen S.A., Schlosser R.J. Revision Surgery Rates in Chronic Rhinosinusitis with Nasal Polyps: Meta-Analysis of Risk Factors. Int Forum Allergy Rhinol. 2020;10(2): 199–207. doi: 10.1002/alr.22487.
31. Kowalski M.L. Oral and Nasal Steroids for Nasal Polyps. Curr Allergy Asthma Rep. 2011;11(3):187–188. doi: 10.1007/s11882-011-0192-9.
32. Tuncer U., Soylu L., Aydogan B., Karakus F., Akcali C. The Effectiveness of Steroid Treatment in Nasal Polyposis. Auris Nasus Larynx. 2003;30(3):263– 268. doi: 10.1016/s0385-8146(03)00051-8.
33. Shilenkova V.V. What Do We Know about the Safety of Intranasal Corticosteroids? Voprosy sovremennoy pediatrii = Current Pediatrics. 2012;11(2):122–126. (In Russ.) doi: 10.15690/vsp.v11i2.224.
34. Mygind N., Lund V. Intranasal Corticosteroids for Nasal Polyposis: Biological Rationale, Efficacy, and Safety. Treat Respir Med. 2006;5(2):93– 102. doi: 10.2165/00151829-200605020-00003.
35. Shakhova E.G. The Role of Topical Glucocorticoids in the Treatment of Rhinosinusitis. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology. 2017;82(2):70–73. (In Russ.) doi: 10.17116/otorino201782270-73.
36. Mashkova T.A., Maltsev A.B. Objective Evaluation of the Efficacy of Mometasone Furoate (Nozefrin) in the Treatment of Polypoid Rhinosinusitis. Rossiiskaya rinologiya = Russian Rhinology. 2018;26(4):56– 59. (In Russ.) doi: 10.17116/rosrino20182604156.
37. McDonnell J., Weller K., Pien L.C. Safety of Intranasal Steroids: an Updated Perspective. Curr Allergy Asthma Rep. 2020;20(11):69. doi: 10.1007/s11882-020-00960-2.
38. Rudmik L., Soler Z.M. Medical Therapies for Adult Chronic Sinusitis: A Systematic Review. JAMA. 2015;314(9):926–939. doi: 10.1001/jama.2015.7544.
39. Small C.B., Hernandez J., Reyes A., Schenkel E., Damiano A., Stryszak P. et al. Efficacy and Safety of Mometasone Furoate Nasal Spray in Nasal Polyposis. J Allergy Clin Immunol. 2005;116(6):1275–1281. doi: 10.1016/j.jaci.2005.07.027.
40. Alobid I., Benitez P., Pujols L., Maldonado M., Bernal-Sprekelsen M., Morello A. et al. Severe Nasal Polyposis and Its Impact on Quality of Life. The Effect of a Short Course of Oral Steroids Followed by Long-Term Intranasal Steroid Treatment. Rhinology. 2006;44(1):8–13. Available at: https://rhinologyjournal.com/Abstract.php?id=542.
41. Stjärne P., Mösges R., Jorissen M., Passàli D., Bellussi L., Staudinger H., Danzig M. A Randomized Controlled Trial of Mometasone Furoate Nasal Spray for the Treatment of Nasal Polyposis. Arch Otolaryngol Head Neck Surg. 2006;132(2):179–185. doi: 10.1001/archotol.132.2.179.
42. Kochetkov P.A., Lopatin A.S. Use of Mometasone Furoate in the Treatment of Polyposis Rhinosunisitis. Rossiiskaya rinologiya = Russian Rhinology. 2009;(1)28- 33. (In Russ.) Available at: https://elibrary.ru/item.asp?id=13037629&.
43. Stjärne P., Olsson P., Alenius M. Use of Mometasone Furoate to Prevent Polyp Relapse after Endoscopic Sinus Surgery. Arch Otolaryngol Head Neck Surg. 2009;135(3):296–302. doi: 10.1001/archoto.2009.2.
44. Onrust S.V., Lamb H.M. Mometasone Furoate. A Review of Its Intranasal Use in Allergic Rhinitis. Drugs. 1998;56(4):725–745. doi: 10.2165/00003495-199856040-00018.
45. Demoly P. Safety of Intranasal Corticosteroids in Acute Rhinosinusitis. Am J Otolaryngol. 2008;29(6):403–413. doi: 10.1016/j.amjoto.2007.11.004.
46. Chong L.Y., Head K., Hopkins C., Philpott C., Schilder A.G., Burton M.J. Intranasal Steroids versus Placebo or No Intervention for Chronic Rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011996. doi: 10.1002/14651858.CD011996.pub2.
47. Rimmer J., Fokkens W., Chong L.Y., Hopkins C. Surgical versus Medical Interventions for Chronic Rhinosinusitis with Nasal Polyps. Cochrane Database Syst Rev. 2014;(12):CD006991. doi: 10.1002/14651858.CD006991.pub2.
48. Rot P., Rapiejko P., Jurkiewicz D. Intranasal Steroid Therapy – EPOS 2020. Otolaryngol Pol. 2020;74(3):41–49. doi: 10.5604/01.3001.0014.2449.
49. Passali D., Spinosi M.C., Crisanti A., Bellussi L.M. Mometasone Furoate Nasal Spray: A Systematic Review. Multidiscip Respir Med. 2016;11:18. doi: 10.1186/s40248-016-0054-3.
50. Savvateeva D.M., Kochetkov P.A., Lopatin A.S. The Influence of the Surgical and Medicamental Treatment on the Olfactory Function in the Patients Presenting with Polypous Rhinosinusitis. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology. 2012;77(2):31–35. (In Russ.) Available at: https://mediasphera.ru/issues/vestnik-otorinolaringologii/2012/2/030042-4668201226.
51. Ryazantsev S.V., Budkovaya M.A., Artemyeva E.S., Khamgushkeeva N.N. Rhinosinusitis with Nasal Polyps: Main Aspects of Anti-Relapse Therapy and Recovery of Nasal Breathing. Meditsinskiy sovet = Medical Council. 2019;(20):13–18. (In Russ.) doi: 10.21518/2079-701X-2019-20-13-18.
52. Jorissen M., Bachert C. Effect of Corticosteroids on Wound Healing after Endoscopic Sinus Surgery. Rhinology. 2009;47(3):280–286. doi: 10.4193/Rhin08.227.
Review
For citations:
Sobolev VP, Bidanova DB. The role of intranasal steroid therapy in the treatment of chronic sinusitis with nasal polyps. Meditsinskiy sovet = Medical Council. 2021;(6):74-80. (In Russ.) https://doi.org/10.21518/2079-701X-2021-6-74-80
Views:
748
Email this article 